Your Testosterone Levels — Killing or helping you?

If you haven't gotten your testosterone level, then visit the AndroStat now.
To see what others are saying about the AndroStat, visit this thread.

If you have your testosterone level, here is what it means –

Ready to get in your zone with the AndroSeries?

Just fill out the AndroStat, and get linked to the AndroStacker to start building your AndroSeries stack. Your testosterone level will be automatically filled in, or if you already tested you can link back to the androstat from your email.

We've taken the "testosterone equivalent" values of our AndroSeries products and built them into the AndroStacker program. This allows you to build a stack of AndroSeries products and see the benefits, side-effects and "androgen zone" — so you can make sure you are taking the optimal dose for your custom goals with minimal side-effects.

References:
1. Estrogen and androgen receptors: regulators of fuel homeostasis and emerging targets for diabetes and obesity.
Mauvais-Jarvis F.
Trends Endocrinol Metab. 2011 Jan;22(1):24-33. Epub 2010 Nov 5.

2. Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)–a promising drug target for the treatment of metabolic syndrome.
Masuzaki H, et al.
Curr Drug Targets Immune Endocr Metabol Disord. 2003 Dec;3(4):255-62.

3. Testosterone deficiency and the metabolic syndrome.
Lunenfeld B.
Aging Male. 2007 Jun;10(2):53-6.

4. Gender differences in the cardiovascular effect of sex hormones.
Vitale C, et al
Nat Rev Cardiol. 2009 Aug;6(8):532-42. Epub 2009 Jun 30.

5. The male climacterium: clinical signs and symptoms of a changing endocrine environment.
van den Beld AW, et al.
Prostate Suppl. 2000;10:2-8.

6. Androgens and body fat distribution in men.
Pi-Sunyer FX.
Obes Res. 1993 Jul;1(4):303-5.

7. Androgens and body fat distribution.
Blouin K, et al.
J Steroid Biochem Mol Biol. 2008 Feb;108(3-5):272-80. Epub 2007 Sep 7.

8. Testosterone and regional fat distribution.
Mårin P.
Obes Res. 1995 Nov;3 Suppl 4:609S-612S.

9. Two emerging concepts for elite athletes: the short-term effects of testosterone and cortisol on the neuromuscular system and the dose-response training role of these endogenous hormones.
Crewther BT, et al.
Sports Med. 2011 Feb 1;41(2):103-23. doi: 10.2165/11539170-000000000-00000.

10. Body composition and anthropometry in bodybuilders: regional changes due to nandrolone decanoate administration.
Hartgens F, et al.
Int J Sports Med. 2001 Apr;22(3):235-41.

11. Comparison of the effects of high dose testosterone and 19-nortestosterone to a replacement dose of testosterone on strength and body composition in normal men.
Friedl KE, et al.
J Steroid Biochem Mol Biol. 1991;40(4-6):607-12.

12. Breaking the vicious circle of obesity: the metabolic syndrome and low testosterone by administration of testosterone to a young man with morbid obesity.
Tishova Y, et al.
Arq Bras Endocrinol Metabol. 2009 Nov;53(8):1047-51.

13. Testosterone Threshold Levels and Lean Tissue Mass Targets Needed to Enhance Skeletal Muscle Strength and Function: The HORMA Trial.
Sattler, F et al.
J Gerontol A Biol Sci Med Sci. 2011 Jan;66(1):122-9.

14. Androstenedione does not stimulate muscle protein anabolism in young healthy men.
Rasmussen BB, et al.
J Clin Endocrinol Metab. 2000 Jan;85(1):55-9.

15. Effect of oral androstenedione on serum testosterone and adaptations to resistance training in young men: a randomized controlled trial.
King DS, et al.
JAMA. 1999 Jun 2;281(21):2020-8.

16. Effects of anabolic precursors on serum testosterone concentrations and adaptations to resistance training in young men.
Brown GA, et al.
Int J Sport Nutr Exerc Metab. 2000 Sep;10(3):340-59.

17. Testosterone dose-response relationships in healthy young men.
Bhasin S, et al.
Am J Physiol Endocrinol Metab. 2001 Dec;281(6):E1172-81.

18. Comparative pharmacokinetics of testosterone enanthate and testosterone cyclohexanecarboxylate as assessed by serum and salivary testosterone levels in normal men.
Schürmeyer T, et al.
Int J Androl. 1984 Jun;7(3):181-7.

19. Correlates of low testosterone and symptomatic androgen deficiency in a population-based sample.
Hall SA, et al.
J Clin Endocrinol Metab. 2008 Oct;93(10):3870-7. Epub 2008 Jul 29.

20. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study.
Wu FC, et al.
J Clin Endocrinol Metab. 2008 Jul;93(7):2737-45. Epub 2008 Feb 12.

21. Prevalence of and risk factors for androgen deficiency in middle-aged men in Hong Kong.
Wong SY, et al.
Metabolism. 2006 Nov;55(11):1488-94.

22. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men.
van den Beld AW, et al.
J Clin Endocrinol Metab. 2000 Sep;85(9):3276-82.

23. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study.
Wu FC, et al.
J Clin Endocrinol Metab. 2008 Jul;93(7):2737-45. Epub 2008 Feb 12.

24. Correlates of low testosterone and symptomatic androgen deficiency in a population-based sample.
Hall SA, et al.
J Clin Endocrinol Metab. 2008 Oct;93(10):3870-7. Epub 2008 Jul 29.

25. Androgen treatment of abdominally obese men.
Mårin P, et al.
Obes Res. 1993 Jul;1(4):245-51.

26. Testosterone, body composition and aging.
Vermeulen A, et al.
J Endocrinol Invest. 1999;22(5 Suppl):110-6.

27. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis.
Isidori AM, et al.
Clin Endocrinol (Oxf). 2005 Sep;63(3):280-93.

28. Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints.
Permpongkosol S, et al.
J Sex Med. 2010 Nov;7(11):3765-74. doi: 10.1111/j.1743-6109.2010.01994.x. Epub 2010 Aug 30.

29. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study.
Aversa A, et al.
J Sex Med. 2010 Oct;7(10):3495-503. doi: 10.1111/j.1743-6109.2010.01931.x.

30. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study.
Kalinchenko SY, et al.
Clin Endocrinol (Oxf). 2010 Nov;73(5):602-12. doi: 10.1111/j.1365-2265.2010.03845.x.

31. Dose-dependent effects of testosterone on regional adipose tissue distribution in healthy young men.
Woodhouse LJ, et al.
J Clin Endocrinol Metab. 2004 Feb;89(2):718-26.

32. The erythrocythaemic effects of androgen.
Gardner FH, et al.
Br J Haematol. 1968 Jun;14(6):611-5.

Methylstenbolone

Diagram of molecule

Chemical Name(s):
2,17a-Dimethyl-17b-hydroxy-5a-androst-1-en-3-one
Chemical Formula: C21H32O2
Molecular Weight: 316.5
CAS: NA
Q Qatio: 3.9
Anabolic #: 660
Androgenic #: 170
Oral Bioavailability: Estimated at 50%
AR Binding Affinity: NA
SHBG Binding Affinity: NA
Half Life: NA
Legal Status (US): Not listed as a controlled substance
Average Dose:
5-20mg/day standalone
1-5mg/day when stacked
Average Cycle Length: 2-4 weeks

 

Stimulator
Inhibitor

 

 
-5
-4
-3
-2
-1

0
1
2
3
4
5

Muscle Gain

[][][][][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Strength Gain

[][][][][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Fat Gain (negative indicates fat loss)

[]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Water Retention (extra-cellular bloat)

[][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Aggression

[][][][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Libido

[]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Acne

[]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Hair Loss

[][][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Prostate Enlargement

[][][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Liver Toxicity

[][][][][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Lethargy

[]
-5
-4
-3
-2
-1

0
1
2
3
4
5

 

Characteristics

Although this compound cannot convert to estrogen, it will bind strongly to SHBG, thus increasing freely circulating estrogen (and testosterone). While there is a lack of anecdotal feedback from this compound to tell the real world effect this compound may have on causing gyno, experience with related compounds tell us gyno symptoms may occur.

Users should be very careful with methylstenbolone and start out with a very low dose. This compound will likely produce a rapid increase in intracellular water retention by inhibiting 11-beta hydroxylase and building up levels of mineralcorticoids that will encourage sodium and water retention.

Gains upwards of 20-25lbs in 4 weeks are probably possible with this compound. However the liver toxicity issues would likely be the first reason why someone wouldn’t be able to make incredible gains from this compound. For this reason it would be extremely important to pre-condition the liver with a liver protecting supplement prior to cycling this compound, while continuing use throughout the cycle and during PCT.

The strength increases from this compound will likely encourage weight lifting heavier than tendons and joints are prepared to lift. It is recommended to be cautious of this and to naturally build up strength levels prior to cycling this steroid.

Using a low dose of methylstenbolone with a moderate dose of a non-methylated compound would be an acceptable way to try to limit the side-effects from this compound, although caution would still need to be taken for liver health no matter what dose is used.

Because of the strength and weight gain this compound would offer it would likely be best used as part of a bulking cycle.

Availability: 

UltraDrol by Antaeus Labs

Related Discussion

The Official Methylstenbolone Thread
Posted by Eric

References

Anabolic Pharmacology
Seth Roberts (2009)

Methylepitiostanol (Epistane)

Diagram of molecule

Chemical Name(s):

2a,3a-epithio-17a-methyl-etioallocholan-17b-ol
2a,3a-epithio-17a-methyl-5a-androstan-17b-ol
Chemical Formula: C20H30OS
Molecular Weight: 320.5
CAS: NA
Q Qatio: 12
Anabolic #: 1,100
Androgenic #: 91
Oral Bioavailability: Estimated at 40%
AR Binding Affinity: NA
SHBG Binding Affinity: NA
Half Life: ~6 hours
Legal Status (US): Not listed as a controlled substance
Average Dose:
40-50mg/day standalone
10-20mg/day when stacked
Average Cycle Length: 4-6 weeks
Stimulator
Inhibitor

-5
-4
-3
-2
-1

0
1
2
3
4
5

Muscle Gain

[][][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Strength Gain

[][][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Fat Gain (negative indicates fat loss)

[][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Water Retention (extra-cellular bloat)

[][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Aggression

[]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Libido

[][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Acne

[]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Hair Loss

[][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Prostate Enlargement

[][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Liver Toxicity

[][][]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Lethargy

[]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Characteristics

Methylepitiostanol is a methylated version of the steroid Epitiostanol. It is readily active and does not require conversion. Under the influence of heat methylepitiostanol readily breaks down to 17a-Methyl-androstan-2-en-17b-ol (DMT), a now illegal anabolic steroid.

It does not aromatize, however it is possible that methylepitiostanol may offset estrogen and testosterone from SHBG thus increase the risk of gyno for certain individuals with high SHBG levels. Gyno symptoms from this compound may also be a result of this compounds inability to form a potent androgen such as DHT (to antagonize the effects of estrogen). However, in other cases methylepitiostanol can be used to prevent or reduce gynecomastia from an estrogenic steroid by acting as an aromatase inhibitor to keep estrogen down.

It is a DHT derivative with a fairly moderate androgenic value so the chances of hair loss may be increased in certain sensitive users. Swelling of the prostate may also become an issue. The powerful estrogen suppressing action of this steroid and its 17aa stucture will cause it to negatively influence the cholesterol profile by lowering HDL and increasing LDL. It has also been reported to cause stiff joints, possibly related to its suppressive effect on estrogen levels.

Anecdotal reports of appetite suppression and general fatigue would lead one to believe that the liver stress from this 17aa compound is rather severe. For this reason it is recommended to use a liver protecting supplement prior to and during the use of this steroid.

Methylepitiostanol has a strong anabolic action that will lead to quick gains in lean muscle mass and strength with very little bloat. The gains will appear with minimal fat gain and increased vascularity.

Because methylepitiostanol can negatively affect joint comfort it is recommended to be stacked with an aromatizing or progestational compound. However, it is not recommended to stack this steroid with another 17aa oral.

Common Clones:

Epistane by Innovative Body Enhancement (IBE)
Havoc by Primaforce
Havoc by Recomp Performance Nutrition (RPN)
Epi-MAX by Anabolic Formulations
M14-E by Purus Labs
Methyl-E by Engineered Sports Technology (EST)
E-Max by Juggernaut Nutrition
E-Stane by Competitive Edge Labs (CEL)
Hemaguno by Spectra Force Research
Hemapolin by Starmark Labs
Epi-Mass by Armour Nutrition
Epidrol by Genera Labs
Methyl Freak by Rockhard Formulations
Epistrong by Mrsupps


Related Discussion

The Official Methylepitiostanol (Epistane) Thread
Posted by Eric

References

“2{alpha},3{alpha}-Epithio-5{alpha}-androstan-17ß-yl 1-Methoxycyclopentyl Ether in the Treatment of Advanced Breast Cancer —A Preliminary Clinical Trial”

SOICHI KUMAOKA, M.D., OSAMU TAKATANI, M.D., MINORU YOSHIDA, M.D., SHIGETO MIURA, M.D., TETSUTO TAKAO, M.D., YÜJI HAMANAKA, M.D., MASARU IZUO, M.D. and TADAKAZU OKADA, M.D.
Japanese Journal of Clinical Oncology 4:65-68 (1974)

“Inhibited growth in vivo of a mouse pregnancy-dependent mammary tumor (TPDMT-4) by an antiestrogen, 2alpha, 3alpha-epithio-5alpha-androstan-17beta-ol (10275-S).”
Matsuzawa A, Yamamoto T.Cancer Res. 1976 May;36(5):1598-606.

“Antitumor Effect of Two Oral Steroids, Mepitiostane and Fluoxymesterone, on a Pregnancy-dependent Mouse Mammary Tumor (TPDMT-4)1”
Akio Matsuzawa and Tadashi Yamamoto
Cancer Research 37, 4408-4415, December 1, 1977

Formestane

Diagram of molecule

Chemical Name(s):

4-Hydroxyandrost-4-ene-3, 17-dione
4-hydroxy-4-androstene-3,17-dione
4-Hydroxyandrostenedione
Chemical Formula: C19H26O3
Molecular Weight: 302
CAS: NA
Q Qatio: NA
Anabolic #: NA
Androgenic #: NA
Oral Bioavailability: Estimated at 4%
AR Binding Affinity: NA
SHBG Binding Affinity: NA
Half Life: 2-3 hours oral, Transdermal: Varies by matrix
Legal Status (US): Not listed as a controlled substance
Average Dose:
Aromatase inhibition
100-200mg/day (transdermal)
150-250mg/day (oral)

Anabolic effects
800-1000mg/day (oral)

Average Cycle Length: 4-8 weeks

Stimulator
Inhibitor

-5
-4
-3
-2
-1

0
1
2
3
4
5

Muscle Gain

[]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Strength Gain

[]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Fat Gain (negative indicates fat loss)

[]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Water Retention (extra-cellular bloat)

[]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Aggression

[]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Libido

[]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Acne

[]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Hair Loss

[]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Prostate Enlargement

[]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Liver Toxicity

[]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Lethargy

[]
-5
-4
-3
-2
-1

0
1
2
3
4
5

Characteristics

Formestane is a steroidal aromatase inhibitor, known as a suicidal inhibitor because it permanently binds to the aromatase enzyme.

Formestane was originally used as an injectable for breast cancer patients, but due to its possible androgenic effects it has largely been replaced by non-steroidial AIs in the medical community. Most of its use is now is limited to the bodybuilding community since it is available as a legal dietary supplement for reducing estrogen and increasing testosterone production.

Although formestane can effectively reduce estrogen through oral consumption, its low oral bioavailability has lead to the development of several transdermal based products (which appear to offer higher efficacy at a lower dose).

Relative to 6-oxo and ATD, Formestane is a more potent aromatase inhibitor, which appears to effectively reduce natural estrogen levels by as much as 50% within several days (while higher doses may further suppress estrogen). Because of formestanes potent ability at reducing estrogen it will tend to reduce HDL levels, while increasing LDL levels, thus harming the cholesterol profile. For this reason, it is recommended to limit cycles of formestane to 8 weeks max.

Because formestane also has a strong affinity for the 5a-reductase enzyme it will reduce DHT levels in the body by effectively competing with testosterone for the 5a-reductase.

Formestane converts to the active androgen 4-hydroxytestosterone which has about half the anabolic potency, and about 25% of the androgenic potency as testosterone. This would suggest that fairly high doses of formestane (800-1000mg/day) could lead to some level of anabolic enhancement (although the amount required for this would surely lead to undesirably low estrogen levels).

Formestane is successfully used as a standalone during re-composition cycles to help reduce “bloat” and fat storage. It can also be used as an anti-estrogen to counter aromatization of aromatizing steroids.

Common Clones:

Formestane by Primordial Performance
Formex by Innovative Body Enhancement (IBE)
Formestane by Competitive Edge Labs (CEL)
Formadex by BCS LABS

Related Discussion

The Official Formestane Thread
Posted by Eric

References

Anabolic Pharmacology
Seth Roberts (2009)

%d bloggers like this: